Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan

Objectives To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic re...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2019-02, Vol.26 (2), p.202-210
Main Authors: Harada, Kenichi, Nozawa, Masahiro, Uemura, Motohide, Tatsugami, Katsunori, Osawa, Takahiro, Yamana, Kazutoshi, Kimura, Go, Fujisawa, Masato, Nonomura, Norio, Eto, Masatoshi, Shinohara, Nobuo, Tomita, Yoshihiko, Kondo, Yukihiro, Ochi, Kenya, Anazawa, Yoshio, Uemura, Hirotsugu
Format: Article
Language:English
Subjects:
carcinoma
Cohort analysis
cohort studies
Enzyme inhibitors
Japan
Kidney cancer
Kinases
Medical prognosis
Medical records
Metastases
Metastasis
molecular targeted therapy
Patients
Prognosis
Protein-tyrosine kinase
Rapamycin
renal cell
Renal cell carcinoma
TOR protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results Of 277 eligible patients, 266, 170 and 77 received first‐, second‐ and third‐line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first‐line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second‐line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow‐up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first‐line tyrosine kinase inhibitors in
ISSN:0919-8172
1442-2042
DOI:10.1111/iju.13830